Abstract
Sphingosine-1-phosphate (S1P) is an important regulator of cancer development and progression. Its cellular concentration is controlled predominantly by sphingosine kinase (SK) and sphingosine-1-phosphate lyase (SPL). In the current study we showed that mRNA expressions for both SK and SPL were up-regulated throughout all four disease stages in human breast cancer patients. Exogenous administration of S1P produced a bell-shaped dose response for apoptosis in normal mammary gland MCF12A cells but a sigmoid-shaped apoptotic response in breast cancer MCF7 cells. Co-administration of S1P enhanced the cytotoxicity of anticancer drug docetaxel against MCF7 cells.
MeSH terms
-
Aldehyde-Lyases / genetics
-
Aldehyde-Lyases / metabolism
-
Apoptosis / drug effects
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / enzymology
-
Breast Neoplasms / genetics
-
Breast Neoplasms / pathology
-
Cell Proliferation / drug effects
-
Docetaxel
-
Female
-
Gene Expression Regulation, Enzymologic / drug effects
-
Gene Expression Regulation, Neoplastic / drug effects
-
Humans
-
Lysophospholipids / pharmacology
-
Lysophospholipids / therapeutic use*
-
Phosphotransferases (Alcohol Group Acceptor) / genetics
-
Phosphotransferases (Alcohol Group Acceptor) / metabolism
-
RNA, Messenger / genetics
-
RNA, Messenger / metabolism
-
Sphingosine / analogs & derivatives*
-
Sphingosine / pharmacology
-
Sphingosine / therapeutic use
-
Taxoids / pharmacology
Substances
-
Lysophospholipids
-
RNA, Messenger
-
Taxoids
-
Docetaxel
-
sphingosine 1-phosphate
-
Phosphotransferases (Alcohol Group Acceptor)
-
sphingosine kinase
-
Aldehyde-Lyases
-
sphingosine 1-phosphate lyase (aldolase)
-
Sphingosine